What is Thrombolex?
Founded in 2016 and headquartered in Doylestown, Pennsylvania, Thrombolex is dedicated to the design, development, and distribution of cutting-edge endovascular catheters. These devices are crucial for interventional procedures, particularly catheter-directed thrombolysis (CDT) in patients suffering from arterial, venous, and arteriovenous thromboembolic conditions. The company's focus on innovative technology aims to improve patient outcomes in critical vascular interventions.
How much funding has Thrombolex raised?
Thrombolex has raised a total of $50M across 1 funding round:
Series A
$50M
Series A (2026): $50M with participation from OrbiMed
Key Investors in Thrombolex
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services. They bring extensive experience in life sciences and healthcare business development, supporting companies from early-stage ventures to scaling organizations.
What's next for Thrombolex?
The recent major enterprise-level funding positions Thrombolex for significant expansion and further development of its endovascular catheter technology. This strategic investment is expected to accelerate product commercialization, enhance manufacturing capabilities, and broaden market reach. The company is poised to solidify its standing in the interventional cardiology and vascular surgery markets, driving innovation in the treatment of thromboembolic diseases.
See full Thrombolex company page
